HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

S T van Tiel Selected Research

Necrosis

12/2006Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery.
5/2004Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats.
1/2003Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion.
10/2002Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma.
4/2002Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity.
11/2000Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions.
3/2000Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.
2/2000TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


S T van Tiel Research Topics

Disease

9Sarcoma (Soft Tissue Sarcoma)
12/2006 - 02/2000
8Necrosis
12/2006 - 02/2000
4Neoplasms (Cancer)
12/2004 - 07/2000
2Neoplasm Metastasis (Metastasis)
01/2003 - 04/2002
2Melanoma (Melanoma, Malignant)
04/2002 - 07/2000
2Osteosarcoma (Osteogenic Sarcoma)
03/2001 - 02/2000
1Leukocytosis (Pleocytosis)
03/2001
1Adenocarcinoma
11/2000

Drug/Important Bio-Agent (IBA)

9Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2004 - 02/2000
8Melphalan (Alkeran)FDA LinkGeneric
12/2004 - 02/2000
2CytokinesIBA
10/2002 - 03/2001
2Doxorubicin (Adriamycin)FDA LinkGeneric
04/2002 - 02/2000
1Contrast MediaIBA
12/2004
1liposomal doxorubicin (Doxil)FDA Link
05/2004
1member 1 small inducible cytokine subfamily EIBA
10/2002
1ParaffinIBA
10/2002
1Thromboplastin (Tissue Factor)IBA
10/2002
1Dactinomycin (Actinomycin)FDA LinkGeneric
04/2002
1Interleukin-3 (Interleukin 3)IBA
03/2001
1Histamine (Histamine Dihydrochloride)FDA Link
03/2001
1Nitric Oxide Synthase (NO Synthase)IBA
11/2000
1NG-Nitroarginine Methyl Ester (L-NAME)IBA
11/2000
1SolutionsIBA
07/2000

Therapy/Procedure

2Therapeutics
10/2002 - 03/2001
1Limb Salvage
12/2006
1Injections
03/2001
1Intravenous Administration
03/2001
1Drug Therapy (Chemotherapy)
07/2000